Using your head to tackle influenza diversity.

Area of Science:

• Virology
• Immunology
• Vaccinology

Background:

• Influenza viruses exhibit significant antigenic diversity, complicating the creation of effective vaccines and antiviral therapies.
• The hemagglutinin (HA) protein, particularly its head domain, is a primary target for neutralizing antibodies due to its role in viral entry.

Purpose of the Study:

• To identify and characterize monoclonal antibodies capable of cross-neutralizing diverse influenza virus subtypes.
• To explore the potential of HA head-targeting antibodies for broad-spectrum influenza protection.

Main Methods:

• Isolation and characterization of monoclonal antibodies targeting the hemagglutinin head domain.
• In vitro neutralization assays against various influenza A (H1N1, H3N2) and influenza B virus strains.
• Analysis of antibody binding epitopes on the hemagglutinin head.

Main Results:

• Identification of monoclonal antibodies that exhibit potent neutralizing activity against both A(H1N1) and A(H3N2) influenza virus subtypes.
• Discovery of antibodies capable of cross-neutralizing drifted influenza B virus strains.
• Demonstration that targeting the hemagglutinin head domain can elicit broad-spectrum neutralization.

Conclusions:

• Monoclonal antibodies targeting the influenza hemagglutinin head domain represent a promising strategy for developing broad-spectrum influenza countermeasures.
• These findings advance the development of universal influenza vaccines and therapies by addressing viral diversity.